Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for modulating gastric secretion using prokineticin receptor antagonists

a technology of prokineticin and receptor antagonist, which is applied in the field of gastric diseases, can solve the problems of nausea, vomiting, and nausea of people with ulcers, and achieve the effects of reducing the risk of ulcers

Inactive Publication Date: 2007-03-22
ZHOU QUN YONG
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Gastrointestinal problems are common.
While many digestive problems are more common as people get older, they can occur at any age, even in children, and strike regardless of gender, ethnic or socioeconomic backgrounds.
The burning and pressure symptoms of heartburn can last as long as 2 hours and are often worsened by eating food.
People with ulcers can experience a gnawing, burning pain in the upper abdomen; nausea; vomiting; loss of appetite; and weight loss.
However, these medications fail to alleviate symptoms in a significant number of patients, up to 50% of patients for certain classes of medications.
Such patients continue to experience gastrointestinal discomfort that many would agree has reduced their quality of life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for modulating gastric secretion using prokineticin receptor antagonists
  • Methods for modulating gastric secretion using prokineticin receptor antagonists
  • Methods for modulating gastric secretion using prokineticin receptor antagonists

Examples

Experimental program
Comparison scheme
Effect test

example i

Prokineticin Receptor Antagonists Reduce Prokineticin Receptor-Mediated Calcium Mobilization

[0108] This example shows the ability prokineticin receptor antagonists to reduce prokineticin receptor 1 (PKR1)-mediated calcium mobilization and prokineticin receptor 2 (PKR2)-mediated calcium mobilization.

[0109] To determine whether various modified prokineticins (PKs) have the ability to modulate PK receptor function, the modified prokineticins were tested for their ability to function as agonists or antagonists in PK receptor-mediated calcium mobilization assays. Shown in Table 2 below are the structures of several of the modified prokineticins tested.

[0110] An aequorin-based luminescent assay for measuring mobilization of intracellular Ca2+ was performed essentially as described in Liu et al., supra, (2002). Chinese hamster ovary (CHO) cells stably expressing photoprotein aequorin and HPKR1 or hPKR2 were used for this assay. Briefly, the cells was charged in Opti MEM containing 30 μM...

example ii

Expression of PK1 and PK1 Receptor in Mouse Stomach

[0116] This example shows that prokineticin 1 (PK1) and PK1 receptor are expressed in mouse stomach.

[0117] Expression of PK1 mRNA in the fundic area of the mouse stomach was determined using in situ hybridization with a mouse PK1 probe (nucleotides 1 to 682 of GenBank accession number AF487281) on sections of adult mouse stomach. FIGS. 5A, B, C and F show dark field emulsion-dipped images of mouse stomach tissue. FIGS. 5D and E show Nissl-stained bright field images. Expression of PK1 mRNA is evidenced by the bright pattern of signal in gastric gland areas of the stomach tissue, as shown in FIGS. A, B, C and F.

[0118] Expression of PK1 receptor mRNA in the fundic area of mouse stomach was determined using in situ hybridization with a mouse PKR1 probe (nucleotides 1457 to 2556 of GenBank accession number AF487278) in sections of adult mouse stomach. FIGS. A, B and C are dark field emulsion-dipped images of mouse stomach tissue. Exp...

example iii

Expression of PK1 and PK1 Receptor in Mouse Stomach

[0122] This example shows a method for an in vitro cell-based assay for determining the effect of modulating PK receptor on gastric acid or pepsinogen secretion.

[0123] Gastric glands for use in the in vitro assay are prepared by dispersing gastric glands from rabbit fundic mucosa according to the method of Berglindh and Öbrink, Acta Physiol Scand. 96(2):150-9 (1976). Rabbit glands are obtained from New Zealand white rabbits (2-3 kg body weight), which are anesthetised with 50 mg / kg ketamine and 5 mg / kg xylazine. PBS is perfused under pressure through the gastric vasculature until the stomach doubles in volume; the stomach is then removed, rinsed in PBS and the fundus separated. The fundic tissue is placed on a warm surface while the serosa is removed and the mucosa scraped off the tunica muscularis and cut into small pieces. Mucosal tissue is incubated at 37° C. for 30 minutes in 50 ml collagenase solution while being gassed with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:3, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:3, and (b) from 0 to 9 of amino acids 78 to 86 of SEQ ID NO:3, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21). In another embodiment, the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:6, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:6, and (b) from 0 to 4 of amino acids 78 to 81 of SEQ ID NO:6, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21).

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] Under 35 USC § 120, this application is a continuation application of U.S. application Ser. No. 10 / 811,328 filed Mar. 25, 2004,now issued as U.S. Pat. No. 7,115,560; which claims the benefit under 35 USC § 119(e) to U.S. Application Ser. No. 60 / 457,891 filed Mar. 25, 2003, now abandoned. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.BACKGROUND OF THE INVENTION [0002] This invention relates generally to gastrological diseases and, more specifically, to modulating gastric acid and pepsinogen secretion to reduce or treat such diseases. [0003] Gastrointestinal problems are common. Most people have experienced some form of gastrointestinal upset in their lives: nausea, vomiting or diarrhea associated with the flu, or indigestion after eating excessively. Over 95 million Americans have experienced gastrointestinal upset, and over 10 million America...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17A61KA61P1/04C07K14/00C07K14/47
CPCC07K14/47A61P1/04
Inventor ZHOU, QUN-YONG
Owner ZHOU QUN YONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products